| 1. REGISTRATION NO. <br> $23-R-0061$ | CUSTOMER NO. <br>  |
| :--- | :---: |

## FORM APPROVED OMB NO. 0579-0036

2. HEADQUARTERS RESEARCH FACILITY (Name and Address, as registered with USDA, include Zip Code)

MILLENNIUM BIORESEARCH INC
1765 WENTZ ROAD
P.O. BOX 178

SPINNERSTOWN, PA 18967
(215) 536-4110
3. REPORTING FACILITY (List all locations where animals were housed or used in actual research, testing, teaching, or experimentation, or held for these purposes. Attach additional sheets if necessary.)


1) Professionally acceptable standards governing the care, treatment, and use of animals, including appropriate use of anesthetic, analgesic, and tranquilizing drugs, prior to, during. and following actual research, teaching, testing, surgery, or experimentation were followed by this research facility.
2) Each principal investigator has considered alternatives to painful procedures.
3) This facility is adhering to the standards and regulations under the Act, and it has required that exceptions to the standards and regulations be specified and explained by the principal investigator and approved by the Institutional Animal Care and Use Committee (IACUC). A summary of all the exceptions is attached to this annual report. In addition to identifying the IACUC-approved exceptions, this summary includes a brief explanation of the exceptions, as well as the species and number of animals affected.
4) The attending veterinarian for this research facility has appropriate authority to ensure the provision of adequate veterinary care and to oversee the adequacy of other aspects of animal care and use.

CERTIFICATION BY HEADQUARTERS RESEARCH FACILITY OFFICIAL
(Chief Executive Officer or Legally Responsible Institutional official) I certify that the above is true, correct, and complete (7 U.S.C. Section 2143)
(b)(6), (b)(7)(c)
(AUG 91)

# MB Research Laboratories 

## COLUMN E EXPLANATION - 2006 Facility Registration No: 23-R-0061

Guinea Pigs: The four hundred sixty-four guinea pigs listed in Column E were used on Magnusson-Kligman sensitization evaluations, as described in OECD testing guideline regulations. The Magnusson-Kligman is the favored guinea pig sensitization assay in Europe over the less invasive Buehler method and is used by sponsors pursuing a global market for their product. The purpose of this study is to assess the sensitization potential of a substance following repeated dermal exposure. The initial inductions used for these studies involve the use of Freund's Complete Adjuvant injections which produce an irritant response. This is a regulatory driven protocol and there are no provisions in the test guideline to permit the use of analgesia or anesthetics. The citing for this test guideline is as follows:

- Organization for Economic Cooperation and Development (OECD) Guidelines for Testing of Chemicals, Guideline \#406, Skin Sensitization, Adopted by the Council on July 17, 1992.
Currently, the Local Lymph Node Assay (LLNA) using mice is an accepted method for sensitization studies. However, this study requires the radioactive procedures. In 2002, MB was awarded a Small Business Innovative Research (SBIR) Phase II grant for the development and commercialization of a Local Lymph Node Assay using mice but eliminating the need for radioactive procedures. This Phase II research has been successfully completed. MB Research is currently conducting these studies for commercial clients. However, the regulatory agencies, i.e., FHSA, EPA, OECD, have not yet adopted this LLNA version as an approved test guideline for sensitization studies, so it cannot be used as an alternative to either the Magnusson-Kligman or Buehler Methods.
Rabbits: The two hundred fifty-four rabbits listed in Section E of the Annual Report were used in EPA, OECD or FHSA dermal or ocular irritation/corrosion studies and dermal toxicity studies in which the use of anesthetics has the potential to mask or worsen the responses being investigated. The purpose of these studies is to determine the irritant or corrosive effect of a substance when applied to the skin or eye. In cases where there is reason to believe that ocular or dermal reactions may be severe, MB recommends to the study sponsor that only one rabbit be tested. In cases where the reaction is severe, the sponsor is notified and the animals are humanely sacrificed to avoid further distress. The citings for these studies are as follows:
- OECD Guidelines for Testing of Chemicals:
- Guideline \#402, Acute Dermal Toxicity in Rabbits, Adopted February 24, 1987
- Guideline \#404, Acute Dermal Irritation/Corrosion, Adopted by the Council April 2002
- Guideline \#405, Acute Eye Irritation/Corrosion, Adopted by the Council on April 2002
- EPA Office of Prevention, Pesticides and Toxic Substances (OPPTS), Health Effects Test Guidelines:
- Guideline \#870.2400, Acute Eye Irritation, effective August 1998
- Guideline \#870.2500, Acute Dermal Irritation, effective August 1998
- Guideline \#870.1200, Acute Dermal Toxicity, effective August 1998
- FHSA - Federal Hazardous Substance Act
- 16 CFR 1500.40, Acute Dermal Toxicity
- 16 CFR 1500.41, Primary Dermal Irritation
- 16 CFR 1500.42, Primary Eye Irritation


Millennium BioResearch Inc., (dba/MB Research Laboratories)

